ResearcherUniversity of FreiburgActive in the last 2 years
Wilfried Reichardt
Matched on ORCID iD 0000-0002-8888-399X; OpenAlex author ID A5066482184. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 2 papers
Papers 5
- Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Co-author DOI 10.1038/s41392-025-02563-7↗
- Immunomodulatory impact of PTPN11 /SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer Co-author DOI 10.64898/2026.05.23.727401↗
- 19Fluorine-MRI Based Longitudinal Immuno-Microenvironment-Monitoring for Pancreatic Cancer. Co-author DOI 10.1002/jmri.29589↗
- Adaptive resistance to SHP2-based vertical RAS-pathway inhibition in pancreatic cancer involves multifaceted routes towards dedifferentiation Co-author DOI 10.1101/2025.09.09.25335395↗
- The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Co-author DOI 10.1038/ncb3513↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Asma Y. Alrawashdeh · 4 shared papers, 2025–2026 · strength 0.85
- Paper 19Fluorine-MRI Based Longitudinal Immuno-Microenvironment-Monitoring for Pancreatic Cancer. DOI 10.1002/jmri.29589↗
- Paper Immunomodulatory impact of PTPN11 /SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer DOI 10.64898/2026.05.23.727401↗
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7↗
- Philipp Hafner · 4 shared papers, 2025–2026 · strength 0.85
- Paper 19Fluorine-MRI Based Longitudinal Immuno-Microenvironment-Monitoring for Pancreatic Cancer. DOI 10.1002/jmri.29589↗
- Paper Immunomodulatory impact of PTPN11 /SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer DOI 10.64898/2026.05.23.727401↗
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7↗
- Dietrich Alexander Ruess · 4 shared papers, 2025–2026 · strength 0.85
- Paper 19Fluorine-MRI Based Longitudinal Immuno-Microenvironment-Monitoring for Pancreatic Cancer. DOI 10.1002/jmri.29589↗
- Paper Immunomodulatory impact of PTPN11 /SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer DOI 10.64898/2026.05.23.727401↗
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7↗
- Melanie Boerries · 4 shared papers, 2017–2026 · strength 0.68
- Paper Immunomodulatory impact of PTPN11 /SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer DOI 10.64898/2026.05.23.727401↗
- Paper Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. DOI 10.1038/s41392-025-02563-7↗
- Paper Adaptive resistance to SHP2-based vertical RAS-pathway inhibition in pancreatic cancer involves multifaceted routes tow… DOI 10.1101/2025.09.09.25335395↗
- Xun Chen · 2 shared papers, 2025 · strength 0.42
- Friederike Inga Nollmann · 1 shared paper, 2026 · strength 0.20
- Oliver Schilling · 1 shared paper, 2026 · strength 0.20
- Uwe A. Wittel · 1 shared paper, 2026 · strength 0.20
- Angela M. Krebs · 1 shared paper, 2017 · strength 0.06
- Marc P. Stemmler · 1 shared paper, 2017 · strength 0.06
- Thomas Brabletz · 1 shared paper, 2017 · strength 0.06
- Christian P. Pilarsky · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.